BR9813381A - "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" - Google Patents
"derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"Info
- Publication number
- BR9813381A BR9813381A BR9813381-0A BR9813381A BR9813381A BR 9813381 A BR9813381 A BR 9813381A BR 9813381 A BR9813381 A BR 9813381A BR 9813381 A BR9813381 A BR 9813381A
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- integer
- attached
- lower alkyl
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98534797A | 1997-12-04 | 1997-12-04 | |
PCT/US1998/025669 WO1999028300A1 (en) | 1997-12-04 | 1998-12-03 | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9813381A true BR9813381A (pt) | 2000-10-03 |
Family
ID=25531403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9813381-0A BR9813381A (pt) | 1997-12-04 | 1998-12-03 | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1036065B1 (pt) |
JP (3) | JP4783502B2 (pt) |
KR (1) | KR100544787B1 (pt) |
CN (1) | CN1284066A (pt) |
AR (1) | AR017807A1 (pt) |
AT (1) | ATE266643T1 (pt) |
AU (1) | AU744798B2 (pt) |
BR (1) | BR9813381A (pt) |
CA (1) | CA2312334A1 (pt) |
DE (1) | DE69823868T2 (pt) |
DK (1) | DK1036065T3 (pt) |
ES (1) | ES2216339T3 (pt) |
HU (1) | HUP0004557A3 (pt) |
IL (2) | IL136388A0 (pt) |
NO (2) | NO317292B1 (pt) |
NZ (1) | NZ504667A (pt) |
PL (1) | PL341009A1 (pt) |
PT (1) | PT1036065E (pt) |
RU (1) | RU2235092C2 (pt) |
SK (1) | SK8542000A3 (pt) |
TW (1) | TW577878B (pt) |
WO (1) | WO1999028300A1 (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002254265B2 (en) * | 1997-12-04 | 2008-05-15 | Allergan, Inc. | Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors |
ATE266643T1 (de) * | 1997-12-04 | 2004-05-15 | Allergan Inc | Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
US6294553B1 (en) * | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6593324B2 (en) | 2000-03-01 | 2003-07-15 | Orion Corporation | Dervatives of quinoline as alpha-2 antagonists |
JP2006036636A (ja) * | 2000-11-22 | 2006-02-09 | Nippon Shinyaku Co Ltd | 消化管機能障害治療剤及びスクリーニング方法 |
NZ535950A (en) | 2002-04-03 | 2007-11-30 | Orion Corp | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
WO2003088992A1 (fr) * | 2002-04-22 | 2003-10-30 | Takeda Chemical Industries, Ltd. | Nouvelle methode de criblage |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
ATE380551T1 (de) * | 2002-10-08 | 2007-12-15 | Allergan Inc | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
MXPA05003664A (es) * | 2002-10-08 | 2005-06-08 | Allergan Inc | Agonistas del adrenoceptor alfa 2b o 2b/2c para tratamiento de neurodegeneracion. |
AU2005287038B2 (en) | 2004-09-20 | 2012-02-02 | Janssen Pharmaceutica N.V. | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
PL1796664T3 (pl) | 2004-09-20 | 2014-04-30 | Janssen Pharmaceutica Nv | Nowe, zawierające heteroatom, pochodne tetracykliczne użyteczne jako modulatory receptora steroidowego hormonu płci |
WO2006036497A2 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
CA2581828A1 (en) | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
JP4986856B2 (ja) * | 2004-09-28 | 2012-07-25 | アラーガン、インコーポレイテッド | 特異的または選択的α2アドレナリン作動剤としての不置換および置換4−ベンジル−1,3−ジヒドロ−イミダゾール−2−チオンならびにその使用方法 |
US7390829B2 (en) | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
RU2008110902A (ru) * | 2005-08-25 | 2009-09-27 | Шеринг Корпорейшн (US) | Агонисты адренорецепторов альфа а2с |
US7592362B2 (en) | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
ES2338716T3 (es) * | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
EA200870452A1 (ru) * | 2006-04-20 | 2009-04-28 | Янссен Фармацевтика Н.В. | Производные замещенного пиразинона для применения в качестве лекарственных средств |
US20090281099A1 (en) * | 2006-05-22 | 2009-11-12 | Andres-Gil Jose Ignacio | Substituted pyrazinone derivatives for use as a medicine |
AU2007312390B2 (en) | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
ATE533755T1 (de) | 2006-11-02 | 2011-12-15 | Hoffmann La Roche | Substituierte 2-imidazole als modulatoren der mit spurenaminen assoziierten rezeptoren |
WO2008058867A2 (en) * | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
CN101190218B (zh) * | 2006-11-20 | 2010-12-22 | 四川科瑞德制药有限公司 | 替扎尼定及其衍生物在制备抗焦虑症药物中的用途 |
ATE509628T1 (de) | 2006-12-13 | 2011-06-15 | Hoffmann La Roche | Neue 2-imidazole als liganden für trace amine associated receptors (taar) |
US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
US7868020B2 (en) | 2007-01-12 | 2011-01-11 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
US8119807B2 (en) | 2007-01-12 | 2012-02-21 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
WO2008086131A1 (en) | 2007-01-12 | 2008-07-17 | Allergan, Inc. | Naphthylmethylimidizoles as therapeutic agents |
EP2114906B1 (en) | 2007-02-02 | 2014-08-06 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands for cns disorders |
RU2009134059A (ru) | 2007-02-13 | 2011-03-20 | Шеринг Корпорейшн (US) | Функционально селективные агонисты альфа2с адренорецептора |
CN101657429A (zh) | 2007-02-13 | 2010-02-24 | 先灵公司 | 功能选择性α2C肾上腺素能受体激动剂 |
JP2010518161A (ja) | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | 機能選択性α2Cアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体 |
CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
EP2160386B1 (en) * | 2007-05-23 | 2012-07-11 | Allergan, Inc. | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
CN101318020B (zh) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | 抗焦虑或/和抗抑郁的药物组合物及用途 |
MX2009013742A (es) | 2007-07-02 | 2010-01-26 | Hoffmann La Roche | 2-imidazolinas. |
EP2173719A1 (en) | 2007-07-03 | 2010-04-14 | F. Hoffmann-Roche AG | 4-imidazolines and their use as antidepressants |
CN101778628B (zh) * | 2007-07-17 | 2013-02-06 | 阿勒根公司 | 治疗焦虑的方法 |
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
AU2008281918A1 (en) | 2007-07-27 | 2009-02-05 | F. Hoffmann-La Roche Ag | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands |
EP2185502A1 (en) | 2007-08-03 | 2010-05-19 | F. Hoffmann-Roche AG | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
WO2009020578A1 (en) * | 2007-08-06 | 2009-02-12 | Schering Corporation | Alpha2c adrenoreceptor agonists |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
WO2009091735A1 (en) * | 2008-01-18 | 2009-07-23 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
WO2009105504A2 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
CA2724293A1 (en) * | 2008-05-13 | 2009-11-19 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
DE102008001932A1 (de) | 2008-05-21 | 2009-11-26 | Bayer Cropscience Ag | Substiuierte Spiroisoxazoline |
US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
EP2356106A1 (en) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
EP3093017B1 (en) * | 2010-11-16 | 2021-01-06 | Allergan, Inc. | Pharmaceutical composition comprising (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treating optic neuropathy |
US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
US9095576B2 (en) | 2011-11-21 | 2015-08-04 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
EP3757102A1 (en) | 2016-03-17 | 2020-12-30 | F. Hoffmann-La Roche AG | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
CN110240542B (zh) * | 2019-06-24 | 2020-05-12 | 牡丹江医学院 | 一种选择性β1-肾上腺素受体抑制剂及其在制备心血管疾病药物中的用途 |
WO2023067518A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | Process |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU85747A1 (fr) * | 1985-01-28 | 1986-08-04 | Continental Pharma | Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives |
FI864570A0 (fi) * | 1986-11-11 | 1986-11-11 | Farmos Oy | Terapeutiskt anvaendbar foerening. |
US4882343A (en) * | 1987-08-28 | 1989-11-21 | G. D. Searle & Co. | Biarylalkylimidazole derivatives as anti-depressants |
JPH01242571A (ja) * | 1988-03-22 | 1989-09-27 | Mitsui Petrochem Ind Ltd | イミダゾール誘導体の製造方法 |
GB8823980D0 (en) * | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
WO1993012107A1 (en) * | 1991-12-18 | 1993-06-24 | Schering Corporation | Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring |
AU5118493A (en) * | 1992-10-06 | 1994-04-26 | Tokyo Tanabe Company Limited | Aromatase inhibitor |
CA2220517A1 (en) * | 1995-05-12 | 1996-11-14 | Allergan | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US5621113A (en) * | 1996-03-28 | 1997-04-15 | Ortho Pharmaceutical Corporation | 4-[(thien-2-yl)methyl]-imidazole analgesics |
US5750720A (en) * | 1996-03-28 | 1998-05-12 | Ortho Pharmaceutical Corporation | 4- (thien-3-yl)methyl!-imidazole analgesics |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
ATE266643T1 (de) * | 1997-12-04 | 2004-05-15 | Allergan Inc | Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren |
-
1998
- 1998-12-03 AT AT98962883T patent/ATE266643T1/de not_active IP Right Cessation
- 1998-12-03 DK DK98962883T patent/DK1036065T3/da active
- 1998-12-03 EP EP98962883A patent/EP1036065B1/en not_active Expired - Lifetime
- 1998-12-03 ES ES98962883T patent/ES2216339T3/es not_active Expired - Lifetime
- 1998-12-03 PT PT98962883T patent/PT1036065E/pt unknown
- 1998-12-03 RU RU2000114169/04A patent/RU2235092C2/ru not_active IP Right Cessation
- 1998-12-03 DE DE69823868T patent/DE69823868T2/de not_active Expired - Fee Related
- 1998-12-03 BR BR9813381-0A patent/BR9813381A/pt not_active Application Discontinuation
- 1998-12-03 JP JP2000523194A patent/JP4783502B2/ja not_active Expired - Fee Related
- 1998-12-03 CN CN98813359A patent/CN1284066A/zh active Pending
- 1998-12-03 AU AU18025/99A patent/AU744798B2/en not_active Ceased
- 1998-12-03 KR KR1020007006072A patent/KR100544787B1/ko not_active IP Right Cessation
- 1998-12-03 WO PCT/US1998/025669 patent/WO1999028300A1/en active IP Right Grant
- 1998-12-03 NZ NZ504667A patent/NZ504667A/xx unknown
- 1998-12-03 SK SK854-2000A patent/SK8542000A3/sk unknown
- 1998-12-03 IL IL13638898A patent/IL136388A0/xx not_active IP Right Cessation
- 1998-12-03 HU HU0004557A patent/HUP0004557A3/hu unknown
- 1998-12-03 EP EP04001074A patent/EP1413576A3/en not_active Withdrawn
- 1998-12-03 PL PL98341009A patent/PL341009A1/xx unknown
- 1998-12-03 CA CA002312334A patent/CA2312334A1/en not_active Abandoned
- 1998-12-04 AR ARP980106173A patent/AR017807A1/es not_active Application Discontinuation
- 1998-12-15 TW TW087120287A patent/TW577878B/zh not_active IP Right Cessation
-
2000
- 2000-05-26 IL IL136388A patent/IL136388A/en unknown
- 2000-05-30 NO NO20002773A patent/NO317292B1/no unknown
-
2003
- 2003-12-10 NO NO20035490A patent/NO20035490D0/no not_active Application Discontinuation
-
2010
- 2010-05-26 JP JP2010120662A patent/JP2010209111A/ja not_active Withdrawn
-
2013
- 2013-09-17 JP JP2013191591A patent/JP2014012724A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9813381A (pt) | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" | |
RU2319701C2 (ru) | ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I | |
PE20070336A1 (es) | Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
MA27991A1 (fr) | Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3 | |
PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
DE69007740D1 (de) | Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole. | |
EA200500054A1 (ru) | Новые соединения, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы | |
MA27728A1 (fr) | Antagonistes des recepteurs de cgrp | |
BRPI0408362A (pt) | combinação de um antagonista de receptor de aldosterona e um agente antidiabético | |
DE69331190D1 (de) | Überbrückte azabicyclische derivate als substanz p antagonisten | |
ATE366724T1 (de) | Kondensierte heterocyclische derivate | |
RU2001107028A (ru) | Соединения в качестве селективных агонистов альфа-адренергических рецепторов 2в или 2в/2с | |
SE0302760D0 (sv) | New compounds | |
HK1035724A1 (en) | Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors. | |
DE60231202D1 (de) | Kondensierte heterozyklische verbindungen | |
BR9713808A (pt) | Composto. | |
FI905481A0 (fi) | Substituerade n-(imidazolyl) -alkylalaninderivat. | |
JP2006504738A5 (pt) | ||
EA200200562A1 (ru) | Антагонисты аденозиновых рецепторов и способы их получения и использования | |
KR920019779A (ko) | 치환된 인돌의 n-이미다졸릴 유도체 | |
MA29336B1 (fr) | Derives d'aryl-1,4-pyrazine substitues | |
EA200900808A1 (ru) | Антагонисты рецепторов ангиотензина ii | |
NO20065958L (no) | Tetrasubstituerte imidazolderivater som cannabinoid CB1 reseptormodulatorer med en hoy CB1/CB2 reseptor undertype selektivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: ALLERGAN SALES, LLC (US) |
|
B25A | Requested transfer of rights approved |
Free format text: ALLERGAN, INC (US) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT: CL.8: C07D 233/06, C07D 233/54, C07D 233/56, C07D 401/06, C07D 403/06, C07D 405/06, C07D 407/06, C07D 409/06, C07D 413/10, C07D 493/04, C07D 265/36, C07D 263/28, A61K 31/33, A61K 31/395, A61K 31/4164, S61K 31/4178, A61K 31/4725, A61K 31/5365, A61K 31/542, A61P 27/06, A61P 21/00, A61P 25/00, A61P 25/18, A61P 25/22, A61P 25/24, A61P 9/00, A61P 9/12 Ipc: C07D 233/06 (2008.04), C07D 233/54 (2008.04), C07D |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |